Global pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said ... are part of a wave of obesity medications known ...

Overall, Wall Street has a Strong Buy consensus rating on Eli Lilly stock based on 18 Buys and one Sell recommendation. The average LLY stock price target of $981 implies about 26.6% upside potential.

A decision is expected in the fourth quarter of 2025.

London: The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs ... Wegovy and Zepbound are part of ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight ...

The World Health Organization (WHO) on Thursday announced its support for weight-loss drugs in adults globally. The organization plans to back GLP-1s like Wegovy and Zepbound to treat obesity in ...